{
  "id": "5c6e05f37c78d69471000049",
  "type": "factoid",
  "question": "RV3-BB vaccine is used for prevention of which viral infection?",
  "ideal_answer": "The RV3-BB human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26318715",
    "http://www.ncbi.nlm.nih.gov/pubmed/29688121",
    "http://www.ncbi.nlm.nih.gov/pubmed/28059609",
    "http://www.ncbi.nlm.nih.gov/pubmed/30145099",
    "http://www.ncbi.nlm.nih.gov/pubmed/23597719",
    "http://www.ncbi.nlm.nih.gov/pubmed/28481726"
  ],
  "snippets": [
    {
      "text": "Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688121",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Serological responses to rotavirus NSP2 occur following wild-type infection; however, it is unknown if serological responses to NSP2 occur following administration of rotavirus vaccines. The phase IIa immunogenicity trial of RV3-BB provided an opportunity to investigate the serological responses to NSP2 following vaccination.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688121",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Molecular characterisation of rotavirus strains detected during a clinical trial of the human neonatal rotavirus vaccine (RV3-BB) in Indonesia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30145099",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: The RV3-BB human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30145099",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28059609",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This study aimed to investigate the effect of rotavirus specific maternal antibodies on the serum IgA response or stool excretion of vaccine virus after any dose of an oral rotavirus vaccine, RV3-BB, in parallel to a Phase IIa clinical trial conducted at Dunedin Hospital, New Zealand.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28059609",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: Forty infants received 3 doses of RV3-BB rotavirus vaccine and were included in the analysis of the neonatal and infant groups.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28059609",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The level of IgA in colostrum or breast milk and level of placental IgG and SNA did not impact on the serum IgA response or stool excretion following 3 doses of RV3-BB Rotavirus Vaccine administered using either a neonatal or infant schedule in New Zealand infants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28059609",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28481726",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The RV3-BB human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28481726",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RV3-BB rotavirus vaccine has been developed as a rotavirus vaccine candidate for administration at birth.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23597719",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The RV3-BB human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28481726",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND The RV3-BB human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30145099",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION A single dose of RV3-BB rotavirus vaccine was well tolerated in adults, children and infants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23597719",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RV3-BB rotavirus vaccine has been developed as a rotavirus vaccine candidate for administration at birth.<br><b>METHODS</b>: A single-centre, double-blind, randomised placebo-controlled Phase I study evaluated the safety and tolerability of a single oral dose of the second generation RV3-BB rotavirus vaccine (8.3\u00d710(6)FFU/mL) in 20 adults, 20 children and 20 infants (10 vaccine and 10 placebo per age cohort).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23597719",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two infants in the placebo group had serological evidence of a rotavirus infection within the 28-day study period: one demonstrated an IgA and the other an SNA response, with wild-type virus replication detected in another infant.<br><b>CONCLUSION</b>: A single dose of RV3-BB rotavirus vaccine was well tolerated in adults, children and infants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23597719",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A birth dose strategy of RV3-BB vaccine has the potential to improve the effectiveness and implementation of rotavirus vaccines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26318715",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RV3-BB rotavirus vaccine has been developed as a rotavirus vaccine candidate for administration at birth.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23597719",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A single dose of RV3-BB rotavirus vaccine was well tolerated in adults, children and infants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23597719",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "rotavirus disease"
}